Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients

BACKGROUND: Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical setting. OBJECTIVE: To describe the charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Escalera, Carlos Rodríguez, Guisado, Ángela María Zurita, Mateo, Francisco Javier, Bahamontes-Rosa, Noemí, Villanueva, María Jesús García
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308486/
https://www.ncbi.nlm.nih.gov/pubmed/35871173
http://dx.doi.org/10.1007/s10067-022-06287-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308486/
https://www.ncbi.nlm.nih.gov/pubmed/35871173
http://dx.doi.org/10.1007/s10067-022-06287-9

Ejemplares similares